Open report — full analysis, no account required.
Sign up to generate reports and read filings that aren't on the open list.
Get notified when VRDN files again. Create a free account and we'll email you the moment its next filing is analyzed.
Get filing alertsViridian locks in WuXi Biologics for 5-year veligrotug manufacturing deal
Filed May 26, 2026 · Period ending May 24, 2026 · ~1 min read
Key Changes
-
high
Viridian secured WuXi Biologics as commercial manufacturer for veligrotug drug supply if approved, positioning the company for potential product launch while maintaining flexibility through non-exclusive arrangement.
Item 1.01 verify on EDGAR → -
medium
Agreement includes binding volume commitments based on monthly forecasts, with fixed pricing through December 2026 then annual volume-based adjustments—creating financial obligations regardless of commercial success.
Item 1.01 verify on EDGAR → -
medium
Five-year term auto-renews unless either party gives 24 months' notice, limiting exit flexibility but providing long-term supply stability for approved product.
Item 1.01 verify on EDGAR → -
medium
Viridian can terminate with 30 days' notice if regulatory changes materially impair WuXi's performance—a hedge against geopolitical risks facing Chinese contract manufacturers.
Item 1.01 verify on EDGAR →
Summary
Viridian Therapeutics has signed a five-year manufacturing agreement with WuXi Biologics to produce veligrotug, its lead drug candidate for thyroid eye disease, if regulatory approval is obtained. The deal positions Viridian for commercial launch while maintaining manufacturing flexibility through a non-exclusive arrangement.
However, the agreement creates financial exposure through binding volume commitments tied to monthly forecasts, with pricing fixed only through year-end 2026 before shifting to annual volume-based adjustments. Retail investors should note this represents a significant step toward commercialization, but also introduces execution risk.
The company will be obligated to purchase committed volumes regardless of actual sales performance. The inclusion of a 30-day termination clause for regulatory changes affecting WuXi provides some protection against geopolitical risks that have increasingly affected Chinese manufacturers. Watch for Viridian's next earnings call or investor presentation for details on anticipated volume commitments and capital requirements to fund manufacturing obligations. Any updates on veligrotug's regulatory timeline will directly impact when these financial commitments begin.
Section-by-Section Diff
Event · Item 1.01 — Entry into a Material Definitive Agreement
Item 1.01 — Entry into a Material Definitive Agreement filed; see Key Changes for terms.
Added in current filing · verify on EDGAR →
On May 24, 2026, Viridian Therapeutics, Inc. (the “Company”) entered into a Commercial Manufacturing Services Agreement (the “Agreement”) with WuXi Biologics (Hong Kong) Limited (“WuXi Biologics”) pursuant to which WuXi Biologics will manufacture and supply the Company’s anticipated long-term supply requirements of veligrotug drug substance and drug product for commercial use (the “Product”), if approved.
Viridian has secured a commercial manufacturing partner for veligrotug, its lead drug candidate, contingent on regulatory approval. WuXi Biologics will serve as a non-exclusive supplier, meaning Viridian retains flexibility to use alternate manufacturers. This agreement positions the company for potential commercial launch if veligrotug receives approval.
Added in current filing · verify on EDGAR →
Under the Agreement, the Company will provide rolling forecasts of volume requirements to WuXi Biologics on a monthly basis (each, a “Forecast”). A portion of each Forecast will be considered a binding and non-cancellable commitment of the Company. The parties have agreed to volume-based pricing under the Agreement. The Product service fee will remain fixed until December 31, 2026 and thereafter may be annually adjusted based on a volume-based structure.
Viridian commits to binding, non-cancellable volume commitments based on monthly forecasts, creating financial obligations. Pricing is fixed through year-end 2026, then subject to annual volume-based adjustments. This structure provides near-term cost certainty but exposes the company to potential price increases and volume commitments regardless of commercial success.
Added in current filing · verify on EDGAR →
The Agreement has an initial term of five years and will automatically renew for successive five-year periods unless either party provides notice of non-renewal at least 24 months prior to the expiration of the initial term or any renewal period.
The agreement locks in a five-year relationship with automatic renewals unless either party gives 24 months' notice. This long-term commitment provides supply stability but requires advance planning to exit, potentially limiting flexibility if better manufacturing options emerge or if veligrotug fails commercially.
Added in current filing · verify on EDGAR →
The Company may terminate the Agreement upon 30 days’ prior notice to WuXi Biologics if there is a change in applicable laws that materially and adversely impacts WuXi’s Biologics ability to perform services under the Agreement.
Viridian can exit the agreement with 30 days' notice if regulatory changes materially impair WuXi's ability to perform. This provision provides an escape clause amid potential geopolitical or regulatory risks affecting Chinese contract manufacturers, which have faced increasing scrutiny from U.S. regulators.
Thanks — your feedback helps us improve report quality.
Figures/quotes linked to EDGAR · Narrative written by AI · May 27, 2026 · How we verify